Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Osteoporosis HELP
Based on 19,094 articles since 2006
||||

These are the 19094 published articles about Osteoporosis that originated from Worldwide during 2006-2015.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Diagnosis and management of menopause: summary of NICE guidance. 2015

Sarri, Grammati / Davies, Melanie / Lumsden, Mary Ann / Anonymous1640975. ·National Collaborating Centre for Women's and Children's Health, Royal College of Gynaecologists and Obstetricians, London NW1 4RG, UK gsarri@rcog.org.uk. · National Collaborating Centre for Women's and Children's Health, Royal College of Gynaecologists and Obstetricians; University College London Hospitals, London, UK. · Reproductive and Maternal Medicine, University of Glasgow; Glasgow Royal Infirmary, Glasgow, UK. · ·BMJ · Pubmed #26563259.

ABSTRACT: -- No abstract --

2 Guideline Recommendations for preventing fracture in long-term care. 2015

Papaioannou, Alexandra / Santesso, Nancy / Morin, Suzanne N / Feldman, Sidney / Adachi, Jonathan D / Crilly, Richard / Giangregorio, Lora M / Jaglal, Susan / Josse, Robert G / Kaasalainen, Sharon / Katz, Paul / Moser, Andrea / Pickard, Laura / Weiler, Hope / Whiting, Susan / Skidmore, Carly J / Cheung, Angela M / Anonymous1150936. ·Department of Medicine (Papaioannou, Adachi, Pickard), Department of Clinical Epidemiology and Biostatistics (Papaioannou, Santesso) and School of Nursing (Kaasalainen), Faculty of Health Sciences, McMaster University, Hamilton, Ont.; Geriatric Education and Research in Aging Sciences Centre (Papaioannou, Pickard, Skidmore), St. Peter's Hospital, Hamilton, Ont.; Department of Medicine (Morin), McGill University Health Centre, Montréal, Que.; Montreal General Hospital (Morin), Montréal, Que.; Department of Medicine (Feldman, Josse, Moser, Cheung) and Department of Physical Therapy (Jaglal), University of Toronto, Toronto, Ont.; Baycrest Geriatric Health Care System (Feldman, Katz, Moser), Toronto, Ont.; St. Joseph's Healthcare (Adachi), Hamilton, Ont.; Division of Geriatric Medicine, Department of Medicine (Crilly), University of Western Ontario, London, Ont.; Department of Kinesiology (Giangregorio), University of Waterloo, Waterloo, Ont.; Institute for Clinical Evaluative Sciences (Jaglal), Toronto, Ont.; Li Ka Shing Knowledge Institute (Josse), St Michael's Hospital, Toronto, Ont.; School of Dietetics and Human Nutrition (Weiler), McGill University, Montréal. Que.; Department of Nutrition and Dietetics (Whiting), University of Saskatchewan, Saskatoon, Sask.; Toronto General Hospital (Cheung), Toronto, Ont. papaioannou@hhsc.ca. · Department of Medicine (Papaioannou, Adachi, Pickard), Department of Clinical Epidemiology and Biostatistics (Papaioannou, Santesso) and School of Nursing (Kaasalainen), Faculty of Health Sciences, McMaster University, Hamilton, Ont.; Geriatric Education and Research in Aging Sciences Centre (Papaioannou, Pickard, Skidmore), St. Peter's Hospital, Hamilton, Ont.; Department of Medicine (Morin), McGill University Health Centre, Montréal, Que.; Montreal General Hospital (Morin), Montréal, Que.; Department of Medicine (Feldman, Josse, Moser, Cheung) and Department of Physical Therapy (Jaglal), University of Toronto, Toronto, Ont.; Baycrest Geriatric Health Care System (Feldman, Katz, Moser), Toronto, Ont.; St. Joseph's Healthcare (Adachi), Hamilton, Ont.; Division of Geriatric Medicine, Department of Medicine (Crilly), University of Western Ontario, London, Ont.; Department of Kinesiology (Giangregorio), University of Waterloo, Waterloo, Ont.; Institute for Clinical Evaluative Sciences (Jaglal), Toronto, Ont.; Li Ka Shing Knowledge Institute (Josse), St Michael's Hospital, Toronto, Ont.; School of Dietetics and Human Nutrition (Weiler), McGill University, Montréal. Que.; Department of Nutrition and Dietetics (Whiting), University of Saskatchewan, Saskatoon, Sask.; Toronto General Hospital (Cheung), Toronto, Ont. · ·CMAJ · Pubmed #26370055.

ABSTRACT: -- No abstract --

3 Guideline 2015 Guidelines for Osteoporosis in Saudi Arabia: Recommendations from the Saudi Osteoporosis Society. 2015

Al-Saleh, Yousef / Sulimani, Riad / Sabico, Shaun / Raef, Hussein / Fouda, Mona / Alshahrani, Fahad / Al Shaker, Mohammad / Al Wahabi, Basma / Sadat-Ali, Mir / Al Rayes, Hanan / Al Aidarous, Salwa / Saleh, Siham / Al Ayoubi, Fakhr / Al-Daghri, Nasser M. ·Yousef Al-Saleh, MD, Assistant Professor,, College of Medicine,, King Saud bin Abdulaziz University for Health Sciences,, Riyadh, Saudi Arabia, T: +966(11)8011111 Ext.13056, F: +966(11)8011111 Ext. 14229, alaslawi@hotmail.com. · ·Ann Saudi Med · Pubmed #26142931.

ABSTRACT: BACKGROUND AND OBJECTIVES: To provide guidelines for medical professionals in Saudi Arabia regarding osteoporosis. DESIGN AND SETTINGS: A panel of 14 local experts in osteoporosis assembled to provide consensus based on the strength of evidence and expert opinions on osteoporosis treatment. PATIENTS AND METHODS: The Saudi Osteoporosis Society (SOS) formed a panel of experts who performed an extensive published studies search to formulate recommendations regarding prevention, diagnosis, and treatment of osteoporosis in Saudi Arabia. Both local and international published studies were utilized whenever available. RESULTS: Dual x-ray absorptiometry (DXA) scanning is still the golden standard for assessing bone mineral density (BMD). In the absence of local, country-specific fracture risk assessment tool (FRAX), the SOS recommends using the USA (White) version of the FRAX tool. All women above 60 years of age should be evaluated for BMD. This is because the panel recognized that osteoporosis and osteoporotic fractures occur at a younger age in Saudi Arabia. Hormone replacement therapy (HRT) is not recommended for treating postmenopausal women with osteoporosis. BMD evaluation should be performed 1-2 years after initiating intervention, and the assessment of bone turnover biomarkers should be performed whenever available to determine the efficacy of intervention. CONCLUSION: All Saudi women above the age of 60 years must undergo a BMD assessment using DXA. Therapy decisions should be formulated with the use of the USA (White) version of the FRAX tool.

4 Guideline 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. 2014

Briot, Karine / Cortet, Bernard / Roux, Christian / Fardet, Laurence / Abitbol, Vered / Bacchetta, Justine / Buchon, Daniel / Debiais, Francoise / Guggenbuhl, Pascal / Laroche, Michel / Legrand, Erik / Lespessailles, Eric / Marcelli, Christian / Weryha, Georges / Thomas, Thierry / Anonymous3170799. · ·Joint Bone Spine · Pubmed #25455041.

ABSTRACT: OBJECTIVES: To update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National Authority for Health (HAS). This update was performed under the aegis of the Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO), in collaboration with four French learned societies (primary-care, gastroenterology, internal medicine, and nephrology). METHODS: A task force composed of members of the medical specialties involved in managing patients with glucocorticoid-induced osteoporosis conducted a systematic literature review according to the method developed by the HAS then used the results to develop updated recommendations. RESULTS: These recommendations are intended for all physicians involved in the management of patients who are scheduled to start, or are taking, long-term glucocorticoid therapy (≥ 3 months) in any dose and for any reason. In postmenopausal women and men older than 50 years of age, treatment is warranted in the presence of any of the following risk factors for fracture: history of bone frailty fracture after 50 years of age, bone mineral density T-score ≤ −2.5 at one or more sites, age ≥ 70 years, and dosage ≥ 7.5 mg/d prednisone-equivalent for longer than 3 months. Bisphosphonates can be used in all these situations; teriparatide can be given as first-line therapy in patients at high fracture risk but is reimbursed by the French statutory health insurance system only in patients having two or more prevalent vertebral fractures. The fracture risk is lower in non-menopausal women and in men younger than 50 years of age,in whom treatment decisions should rest on a case-by-case evaluation. CONCLUSION: These recommendations are intended to clarify the pharmacological management of glucocorticoid-induced osteoporosis.

5 Guideline American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. 2014

Ruggiero, Salvatore L / Dodson, Thomas B / Fantasia, John / Goodday, Reginald / Aghaloo, Tara / Mehrotra, Bhoomi / O'Ryan, Felice / Anonymous930792. ·Clinical Professor, Division of Oral and Maxillofacial Surgery, Stony Brook School of Dental Medicine, Hofstra North Shore-LIJ School of Medicine, New York Center for Orthognathic and Maxillofacial Surgery, Lake Success, NY. Electronic address: sruggie@optonline.net. · Professor and Chair, Associate Dean for Hospital Affairs, Department of Oral and Maxillofacial Surgery, University of Washington School of Dentistry, Seattle, WA. · Chief, Division of Oral Pathology, Department of Dental Medicine, Hofstra North Shore-LIJ School of Medicine , New Hyde Park, NY. · Professor, Department of Oral and Maxillofacial Sciences, Dalhousie University, Halifax, NS, Canada. · Associate Professor, Oral and Maxillofacial Surgery, Assistant Dean for Clinical Research, UCLA School of Dentistry, Los Angeles, CA. · Director, Cancer Institute at St Francis Hospital, Roslyn, NY. · Director, Division of Maxillofacial Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA. · ·J Oral Maxillofac Surg · Pubmed #25234529.

ABSTRACT: Strategies for management of patients with, or at risk for, medication-related osteonecrosis of the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial Surgeons (AAOMS) position papers in 2007 and 2009. The position papers were developed by a special committee appointed by the board and composed of clinicians with extensive experience in caring for these patients and basic science researchers. The knowledge base and experience in addressing MRONJ has expanded, necessitating modifications and refinements to the previous position paper. This special committee met in September 2013 to appraise the current literature and revise the guidelines as indicated to reflect current knowledge in this field. This update contains revisions to diagnosis, staging, and management strategies and highlights current research status. The AAOMS considers it vitally important that this information be disseminated to other relevant health care professionals and organizations.

6 Guideline Osteoporosis in menopause. 2014

Khan, Aliya / Fortier, Michel / Anonymous5100791 / Fortier, Michel / Reid, Robert / Abramson, Beth L / Blake, Jennifer / Desindes, Sophie / Dodin, Sylvie / Graves, Lisa / Guthrie, Bing / Johnston, Shawna / Khan, Aliya / Rowe, Timothy / Sodhi, Namrita / Wilks, Penny / Wolfman, Wendy / Anonymous5110791 / Anonymous5120791. ·Hamilton ON.; Hamilton ON. · Quebec QC.; Quebec QC. · · Kingston ON. · Toronto ON. · Sherbrooke QC. · Quebec QC. · Yellowknife NT. · Vancouver BC. · Dundas ON. ·J Obstet Gynaecol Can · Pubmed #25222365.

ABSTRACT: OBJECTIVE: To provide guidelines for the health care provider on the prevention, diagnosis, and clinical management of postmenopausal osteoporosis. OUTCOMES: Strategies for identifying and evaluating high-risk individuals, the use of bone mineral density (BMD) and bone turnover markers in assessing diagnosis and response to management, and recommendations regarding nutrition, physical activity, and the selection of pharmacologic therapy to prevent and manage osteoporosis. EVIDENCE: Published literature was retrieved through searches of PubMed and The Cochrane Library on August 30 and September 18, 2012, respectively. The strategy included the use of appropriate controlled vocabulary (e.g., oteoporosis, bone density, menopause) and key words (e.g., bone health, bone loss, BMD). Results were restricted to systematic reviews, practice guidelines, randomized and controlled clinical trials, and observational studies published in English or French. The search was limited to the publication years 2009 and following, and updates were incorporated into the guideline to March 2013. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies.

7 Guideline [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms]. 2014

Kiltz, U / Rudwaleit, M / Sieper, J / Krause, D / Chenot, J-F / Stallmach, A / Jaresch, S / Oberschelp, U / Schneider, E / Swoboda, B / Böhm, H / Heiligenhaus, A / Pleyer, U / Böhncke, W-H / Stemmer, M / Braun, J / Anonymous5920790. ·Deutsche Gesellschaft für Rheumatologie (DGRh), -, -, Uta.Kiltz@elisabethgruppe.de. · ·Z Rheumatol · Pubmed #25181971.

ABSTRACT: -- No abstract --

8 Guideline Recommendations of the Brazilian Society of Endocrinology and Metabology (SBEM) for the diagnosis and treatment of hypovitaminosis D. 2014

Maeda, Sergio Setsuo / Borba, Victoria Z C / Camargo, Marília Brasilio Rodrigues / Silva, Dalisbor Marcelo Weber / Borges, João Lindolfo Cunha / Bandeira, Francisco / Lazaretti-Castro, Marise / Anonymous2930790. ·Disciplina de Endocrinologia, Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, SP, Brasil. · Departamento de Clínica Médica, Universidade Federal do Paraná, Curitiba, PR, Brasil. · Departamento de Clínica Médica, Faculdade de Medicina da Univille, Joinville, SC, Brasil. · Disciplina de Endocrinologia, Universidade Católica de Brasília, Brasília, DF, Brasil. · Disciplina de Endocrinologia, Hospital Agamenon Magalhães, Escola de Medicina, Universidade de Pernambuco, Recife, PE, Brasil. · ·Arq Bras Endocrinol Metabol · Pubmed #25166032.

ABSTRACT: OBJECTIVE: The objective is to present an update on the diagnosis and treatment of hypovitaminosis D, based on the most recent scientific evidence. MATERIALS AND METHODS: The Department of Bone and Mineral Metabolism of the Brazilian Society of Endocrinology and Metabology (SBEM) was invited to generate a document following the rules of the Brazilian Medical Association (AMB) Guidelines Program. Data search was performed using PubMed, Lilacs and SciELO and the evidence was classified in recommendation levels, according to the scientific strength and study type. CONCLUSION: A scientific update regarding hypovitaminosis D was presented to serve as the basis for the diagnosis and treatment of this condition in Brazil.

9 Guideline [Preventive activities in women]. 2014

López García-Franco, Alberto / Arribas Mir, Lorenzo / del Cura González, Isabel / Bailón Muñoz, Emilia / Iglesias Piñeiro, M José / Gutiérrez Teira, Blanca / Landa Goñi, Jacinta / Ojuel Solsona, Julia / Fuentes Pujol, Mercè / Alonso Coello, Pablo / Anonymous260925. ·Grupo de la Mujer del PAPPS. · ·Aten Primaria · Pubmed #24950633.

ABSTRACT: -- No abstract --

10 Guideline Bone health in cancer patients: ESMO Clinical Practice Guidelines. 2014

Coleman, R / Body, J J / Aapro, M / Hadji, P / Herrstedt, J / Anonymous1520791. ·Weston Park Hospital, Cancer Research-UK/Yorkshire Cancer Research Sheffield Cancer Research Centre, Sheffield, UK. · CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium. · Multidisciplinary Oncology Institute, Genolier, Switzerland. · Department of Gynecology, Endocrinology and Oncology, Philipps-University of Marburg, Marburg, Germany. · Department of Oncology, Odense University Hospital, Odense, Denmark. · ·Ann Oncol · Pubmed #24782453.

ABSTRACT: There are three distinct areas of cancer management that make bone health in cancer patients of increasing clinical importance. First, bone metastases are common in many solid tumours, notably those arising from the breast, prostate and lung, as well as multiple myeloma, and may cause major morbidity including fractures, severe pain, nerve compression and hypercalcaemia. Through optimum multidisciplinary management of patients with bone metastases, including the use of bone-targeted treatments such as potent bisphosphonates or denosumab, it has been possible to transform the course of advanced cancer for many patients resulting in a major reduction in skeletal complications, reduced bone pain and improved quality of life. Secondly, many of the treatments we use to treat cancer patients have effects on reproductive hormones, which are critical for the maintenance of normal bone remodelling. This endocrine disturbance results in accelerated bone loss and an increased risk of osteoporosis and fractures that can have a significant negative impact on the lives of the rapidly expanding number of long-term cancer survivors. Finally, the bone marrow micro-environment is also intimately involved in the metastatic processes required for cancer dissemination, and there are emerging data showing that, at least in some clinical situations, the use of bone-targeted treatments can reduce metastasis to bone and has potential impact on patient survival.

11 Guideline Polish guidelines for the diagnosis and management of osteoporosis: a review of 2013 update. 2014

Głuszko, Piotr / Lorenc, Roman S / Karczmarewicz, Elżbieta / Misiorowski, Waldemar / Jaworski, Maciej / Anonymous320922. · ·Pol Arch Med Wewn · Pubmed #24694725.

ABSTRACT: To decrease the risk of osteoporotic fractures in Poland, the Multidisciplinary Osteoporotic Forum has set up a joint Working Group including the representatives of the Polish Associations of Orthopedics and Traumatology, Rehabilitation, Gerontology, Rheumatology, Family Medicine, Diabetology, Laboratory Diagnostics, Andropause and Menopause, Endocrinology, Radiology, and the STENKO group as well as experts in the fields of rheumatology, obstetrics, and geriatrics to update the Polish guidelines for the diagnosis and management of osteoporosis in men and postmenopausal women in Poland. The assessment of fracture risk and intervention thresholds was made using the FRAX® calculation tool for Poland. The strength of recommendations was evaluated according to the principles of the Scottish Intercollegiate Guidelines Network and the results have been approved by national consultants. Finally, the Working Group has formulated the updated guidelines and recommended two -step diagnostic and therapeutic procedures. The first stage applies to family physicians or general practitioners and involves the assessment of fracture risk using the FRAX®-BMI to identify patients at high risk of fractures. An osteoporotic fracture remains an absolute indication both for the general practitioner and specialist to implement treatment. At the second stage, the specialist (in an osteoporosis or other specialty clinic) should review the primary or secondary causes of fracture risk, confirm the diagnosis, and introduce an appropriate treatment and monitoring. In patients (men aged >50 years and postmenopausal women) without low-energy fractures, the absolute risk of fractures exceeding 10% should be considered an indication for treatment. The Polish guidelines were compared with other international guidelines in terms of diagnostic measures, pharmacotherapy, as well as calcium and vitamin D supplementation.

12 Guideline EMAS position statement: The management of postmenopausal women with vertebral osteoporotic fracture. 2014

Triantafyllopoulos, Ioannis K / Lambropoulou-Adamidou, Kalliopi / Nacopoulos, Cleopatra C / Papaioannou, Nikolaos A / Ceausu, Iuliana / Depypere, Herman / Erel, C Tamer / Pérez-López, Faustino R / Schenck-Gustafsson, Karin / van der Schouw, Yvonne T / Simoncini, Tommaso / Tremollieres, Florence / Rees, Margaret / Lambrinoudaki, Irene / Anonymous4330781. ·Laboratory of Research for the Musculoskeletal System (LRMS), School of Medicine, University of Athens, 10 Athinas Street, 14561 Kifissia, Greece. Electronic address: sportdoc@otenet.gr. · Medical School, University of Athens, KAT General Hospital, 2 Nikis Street, 14561 Kifissia, Greece. · Medical School, University of Athens, 10 Athinas Street, 14561 Kifissia, Greece. · Laboratory of Research for the Musculoskeletal System (LRMS), School of Medicine, University of Athens, 10 Athinas Street, 14561 Kifissia, Greece. · Department of Obstetrics and Gynecology, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania; Department of Obstetrics and Gynecology, 'Dr. I. Cantacuzino' Hospital, Bucharest, Romania. · Breast Clinic and Menopause Clinic, University Hospital, De Pintelaan 185, 9000 Gent, Belgium. · Department of Obstetrics and Gynecology, Istanbul University, Cerrahpasa School of Medicine, Valikonagi Cad. No. 93/4, Nisantasi, 34365 Istanbul, Turkey. · Department of Obstetrics and Gynecology, Zaragoza University Facultad de Medicina, Hospital Clínico, Zaragoza 50009, Spain. · Department of Medicine, Cardiology Unit and Head Centre for Gender Medicine, Karolinska Institutet and Karolinska University Hospital, Thorax N3:06, SE 17176 Stockholm, Sweden. · Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. · Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy. · Menopause and Metabolic Bone Disease Unit, Hôpital Paule de Viguier, F-31059 Toulouse cedex 09, France. · Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK. · Second Department of Obstetrics and Gynecology, National and Capodestrian University of Athens, Greece. · ·Maturitas · Pubmed #24679890.

ABSTRACT: INTRODUCTION: Osteoporotic vertebral fractures are associated with significant morbidity, excess mortality as well as health and social service expenditure. Additionally, women with a prevalent osteoporotic vertebral fracture have a high risk of experiencing a further one within one year. It is therefore important for the physician to use a diagnostic and therapeutic algorithm for early detection and effective treatment of vertebral fractures. AIMS: The aim of this position statement is to provide and critically appraise evidence on the management of women with a vertebral osteoporotic fracture. MATERIALS AND METHODS: Literature review and consensus of expert opinion. RESULTS AND CONCLUSIONS: The management of women with osteoporotic vertebral fractures includes measures to reduce pain providing early mobility, to support the affected spine ensuring fracture healing, as well as starting treatment for osteoporosis itself. Any other underlying pathology should be sought and treated. Early detection and treatment is essential as there is an increased risk of further fractures in patients with vertebral fractures. Treatment will depend on the underlying causes of bone loss, efficacy in any particular situation, cost and patient preference.

13 Guideline EMAS position statement: Menopause for medical students. 2014

Brockie, Janet / Lambrinoudaki, Irene / Ceausu, Iuliana / Depypere, Herman / Erel, C Tamer / Pérez-López, Faustino R / Schenck-Gustafsson, Karin / van der Schouw, Yvonne T / Simoncini, Tommaso / Tremollieres, Florence / Rees, Margaret / Anonymous1690779. ·Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK. Electronic address: janet.brockie@ouh.nhs.uk. · Second Department of Obstetrics and Gynecology, National and Capodestrian University of Athens, Greece. · Department of Obstetrics and Gynecology, 'Carol Davila' University of Medicine and Pharmacy, Romania; Department of Obstetrics and Gynecology, 'Dr. I. Cantacuzino' Hospital, Bucharest, Romania. · Breast Clinic and Menopause Clinic, University Hospital, De Pintelaan 185, 9000 Gent, Belgium. · Department of Obstetrics and Gynecology, Istanbul University, Cerrahpasa School of Medicine, Valikonagi Cad. No. 93/4, Nisantasi, 34365 Istanbul, Turkey. · Department of Obstetrics and Gynecology, Zaragoza University Facultad de Medicina, Hospital Clínico, Zaragoza 50009, Spain. · Department of Medicine, Cardiology Unit and Head Centre for Gender Medicine, Karolinska Institutet and Karolinska University Hospital, Thorax N3:06, SE 17176 Stockholm, Sweden. · Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. · Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy. · Menopause and Metabolic Bone Disease Unit, Hôpital Paule de Viguier, F-31059 Toulouse cedex 09, France. · Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK. · ·Maturitas · Pubmed #24630127.

ABSTRACT: -- No abstract --

14 Guideline 2014 Female Athlete Triad Coalition consensus statement on treatment and return to play of the female athlete triad: 1st International Conference held in San Francisco, CA, May 2012, and 2nd International Conference held in Indianapolis, IN, May 2013. 2014

De Souza, Mary Jane / Nattiv, Aurelia / Joy, Elizabeth / Misra, Madhusmita / Williams, Nancy I / Mallinson, Rebecca J / Gibbs, Jenna C / Olmsted, Marion / Goolsby, Marci / Matheson, Gordon / Anonymous3210774 / Anonymous3220774 / Anonymous3230774 / Anonymous3240774. ·*Penn State University, Department of Kinesiology, University Park, Pennsylvania; †University of California Los Angeles, Los Angeles, California; ‡Intermountain Healthcare, Salt Lake City, Utah; §Harvard Medical School, Boston, Massachusetts; ¶University of Waterloo, Waterloo, Ontario, Canada; ‖University of Toronto, Toronto, Ontario, Canada; **Hospital for Special Surgery, New York, New York; ††Stanford University, Stanford, California. · ·Clin J Sport Med · Pubmed #24569429.

ABSTRACT: The Female Athlete Triad is a medical condition often observed in physically active girls and women, and involves 3 components: (1) low energy availability with or without disordered eating, (2) menstrual dysfunction, and (3) low bone mineral density. Female athletes often present with 1 or more of the 3 Triad components, and an early intervention is essential to prevent its progression to serious endpoints that include clinical eating disorders, amenorrhea, and osteoporosis. This consensus statement represents a set of recommendations developed following the first (San Francisco, California) and second (Indianapolis, Indianna) International Symposia on the Female Athlete Triad. It is intended to provide clinical guidelines for physicians, athletic trainers, and other health care providers for the screening, diagnosis, and treatment of the Female Athlete Triad and to provide clear recommendations for return to play. The 2014 Female Athlete Triad Coalition Consensus Statement on Treatment and Return to Play of the Female Athlete Triad Expert Panel has proposed a risk stratification point system that takes into account magnitude of risk to assist the physician in decision-making regarding sport participation, clearance, and return to play. Guidelines are offered for clearance categories, management by a multidisciplinary team, and implementation of treatment contracts. This consensus paper has been endorsed by The Female Athlete Triad Coalition, an International Consortium of leading Triad researchers, physicians, and other health care professionals, the American College of Sports Medicine, and the American Medical Society for Sports Medicine.

15 Guideline [Consensus statement: recommendations for the management of metabolic bone disease in human immunodeficiency virus patients]. 2014

Martínez, Esteban / Jódar Gimeno, Esteban / Reyes García, Rebeca / Carpintero, Pedro / Casado, José Luis / Del Pino Montes, Javier / Domingo Pedrol, Pere / Estrada, Vicente / Maalouf, Jorge / Negredo, Eugenia / Ocampo, Antonio / Muñoz-Torres, Manuel / Anonymous3130778 / Anonymous3140778 / Anonymous3150778 / Anonymous3160778. ·Unidad de Enfermedades Infecciosas, Hospital Clínic, Barcelona, España. · Servicio de Endocrinología, Hospital Universitario Quirón, Madrid, España. · Unidad de Endocrinología, Hospital General Universitario Rafael Méndez, Lorca, Murcia, España. Electronic address: rebecarg@yahoo.com. · Servicio de Traumatología, Hospital Universitario Reina Sofía, Córdoba, España. · Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, España. · Servicio de Reumatología, Hospital Universitario de Salamanca, Salamanca, España. · Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau, Barcelona, España. · Medicina Interna/Enfermedades Infecciosas, Hospital Clínico San Carlos, Madrid, España. · Unidad de Metabolismo Mineral, Departamento de Medicina Interna, Hospital de la Santa Creu i Sant Pau, Barcelona, España. · Servicio de Medicina Interna, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, España. · Unidad VIH, Hospital Xeral-Cies, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Pontevedra, España. · Unidad de Metabolismo Óseo, Servicio de Endocrinología, Hospital Universitario San Cecilio, Granada, España. · ·Enferm Infecc Microbiol Clin · Pubmed #24332711.

ABSTRACT: OBJECTIVE: To provide practical recommendations for the evaluation and treatment of metabolic bone disease in human immunodeficiency virus (HIV) patients. PARTICIPANTS: Members of scientific societies related to bone metabolism and HIV: Grupo de Estudio de Sida (GeSIDA), Sociedad Española de Endocrinología y Nutrición (SEEN), Sociedad Española de Investigación Ósea y del Metabolismo Mineral (SEIOMM), and Sociedad Española de Fractura Osteoporótica (SEFRAOS). METHODS: A systematic search was carried out in PubMed, and papers in English and Spanish with a publication date before 28 May 2013 were included. Recommendations were formulated according to GRADE system (Grading of Recommendations, Assessment, Development, and Evaluation) setting both their strength and the quality of supporting evidence. Working groups were established for each major part, and the final resulting document was later discussed in a face-to-face meeting. All the authors reviewed the final written document and agreed with its content. CONCLUSIONS: The document provides evidence-based practical recommendations on the detection and treatment of bone disease in HIV-infected patients.

16 Guideline Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment. 2013

De Sanctis, Vincenzo / Soliman, Ashraf T / Elsedfy, Heba / Yassin, Mohamed / Canatan, Duran / Kilinc, Yurdanur / Sobti, Praveen / Skordis, Nicos / Karimi, Mehran / Raiola, Giuseppe / Galati, Maria Concetta / Bedair, Elsaid / Fiscina, Bernadette / El Kholy, Mohamed / Anonymous1390768. ·Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, Italy. vdesanctis@libero.it · Department of Pediatrics, Division of Endocrinology, Hamad General Hospital Doha, Qatar. · Department of Pediatrics, Ain Shams University, Cairo, Egypt. · Department of Hematology, Alamal Hospital, Hamad Medical Center, Doha, Qatar. · Director of Hemoglobinopathy Diagnosis Center and President of Mediterranean Blood Diseases Foundation, Antalya, Turkey. · Pediatric Hematology and Oncology, Cukurova University, Adana, Turkey. · Department of Pediatrics, Dayanand Medical College, Ludhiana, Punjab, India. · Department of Paediatrics, Division of Pediatric Endocrinology, Makarios Hospital, Nicosia, Cyprus. · Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. · Department of Paediatrics, Pugliese Ciaccio Hospital, Catanzaro, Italy. · Department of Haematology, Thalassaemia and Prenatal Diagnosis Regional Center, Pugliese Ciaccio Hospital, Catanzaro, Italy. · Department of Radiology, Hamad General Hospital, Doha, Qatar. · Department of Pediatrics, NYU School of Medicine, New York, USA. · ·Pediatr Endocrinol Rev · Pubmed #24575552.

ABSTRACT: In recent years, the issue of osteopenia/osteoporosis in children, adolescents and young adults with thalassaemia major (TM) has attracted much attention because it is a prominent cause of morbidity despite adequate transfusion and iron chelation therapy. The reported frequency of osteoporosis, even in well treated TM patients varies from 13.6% to 50% with an additional 45% affected by osteopenia. The pathogenesis of TM-induced osteoporosis is multifactorial. Genetic and acquired factors play role in demineralization of bones in thalassemia. Osteoporosis is characterized by low bone mass and disruption of bone architecture, resulting in reduced bone strength and increased risk of fractures. The significant predictors of fracture prevalence include male gender, hypothyroidism, age, lack of spontaneous puberty in females, active hepatitis, heart disease and diabetes. The early identification of osteopenia and osteoporosis is of paramount importance. This is because delayed diagnosis and inadequate treatment have led to severe osteoporosis, skeletal abnormalities, fractures, spinal deformities, nerve compression and growth failure. dequate hormonal replacement, has been posponed, Effective iron chelation adequate hormonal replacement, improvement of hemoglobin levels, calcium and vitamin D administration and physical activity are currently the main measures for the management of the disease. The use of bisphosphonates in TM patients with osteoporosis is increasing and their positive effect in improving bone mineral density is encouraging. The recommendations of the International Network on Growth Disorders and Endocrine Complications in Thalassaemia (I-CET) for diagnosis and management of osteoporosis in TM are also briefly included in this review.

17 Guideline Canadian Association of Radiologists Technical Standards for Bone Mineral Densitometry Reporting. 2013

Siminoski, Kerry / O'Keeffe, Margaret / Brown, Jacques P / Burrell, Steven / Coupland, David / Dumont, Marcel / Ganguli, S Nimu / Hanley, David A / Law-Dillabough, Amanda / Lévesque, Jacques / Anonymous5210765. ·Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada. Electronic address: kerrygs@telusplanet.net. · ·Can Assoc Radiol J · Pubmed #24314581.

ABSTRACT: -- No abstract --

18 Guideline [Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on adrenal insufficiency and osteoporosis]. 2013

Cornillon, J / Vantyghem, M-C / Couturier, M A / de Berranger, E / François, S / Hermete, E / Maillard, N / Marcais, A / Tabrizi, R / Decanter, C / Duléry, R / Bauters, F / Yakoub-Agha, I / Anonymous60760. ·Service d'hématologie adulte, institut de cancérologie de la Loire, 108 bis, avenue Albert-Raimond, Saint-Priest-en-Jarez, France. · ·Pathol Biol (Paris) · Pubmed #24011963.

ABSTRACT: In the attempt to harmonize clinical practices between different French transplantation centers, the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC) set up the third annual series of workshops which brought together practitioners from all member centers and took place in October 2012 in Lille. Here we report our results and recommendations regarding the management of short and long-term endocrine dysfunction following allogeneic stem cell transplantation. The key aim of this workshop was to give an overview on secondary adrenal insufficiency and osteoporosis post-transplant.

19 Guideline ACOG releases practice bulletin on osteoporosis. 2013

Hauk, Lisa / Anonymous1580756. · ·Am Fam Physician · Pubmed #23944732.

ABSTRACT: -- No abstract --

20 Guideline South African recommendations for the management of rheumatoid arthritis: an algorithm for the standard of care in 2013. 2013

Hodkinson, Bridget / Van Duuren, Elsa / Pettipher, Clive / Kalla, Asgar / Anonymous3880754. ·Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa. drbridget@gmail.com · ·S Afr Med J · Pubmed #23885741.

ABSTRACT: Updated treatment recommendations for the therapy of rheumatoid arthritis (RA) in South Africa advocate early diagnosis, prompt initiation of disease-modifying anti-rheumatic drugs (DMARDs), and an intense treatment strategy where disease activity is assessed with a composite score such as the Simplified Disease Activity Index (SDAI). Frequent assessments and escalation of therapy are necessary until low disease activity (LDA) (SDAI ≤11) or ideally remission (SDAI ≤3.3) is achieved. Synthetic DMARDs may be used as monotherapy or in combination, and can be co-prescribed with low-dose corticosteroids if necessary. Biologic DMARD therapy should be considered for patients who have failed a 6-month trial of at least 3 synthetic DMARDs. All RA patients in SA are at increased risk of tuberculosis (TB), in particular patients using anti-tumour necrosis factor (TNF) biologic therapy. These recommendations provide practical suggestions for the screening and management of TB and other comorbidities, and offer an approach to monitoring of RA patients.

21 Guideline 2013 Up-date of the consensus statement of the Spanish Menopause Society on postmenopausal osteoporosis. 2013

Mendoza, Nicolás / Sánchez-Borrego, Rafael / Villero, José / Baró, Francesc / Calaf, Joaquim / Cancelo, Ma Jesús / Coronado, Pluvio / Estévez, Antonio / Fernández-Moya, Jose M / González, Silvia / Llaneza, Plácido / Neyro, Jose Luis / del Pino, Javier / Rodríguez, Esteban / Ruiz, Elena / Cano, Antonio / Anonymous2750755. ·Department of Obstetrics and Gynecology, University of Granada, Granada, Spain. nicomendoza@telefonica.net · ·Maturitas · Pubmed #23827473.

ABSTRACT: Postmenopausal osteoporosis is a major female health problem that increases morbidity, mortality and healthcare system costs. Considering that gynecologists are the primary health practitioners involved in the treatment of women with osteoporosis in our country, a panel of experts from the Spanish Menopause Society met to establish a set of criteria and procedures for the diagnosis and treatment of this disease based on the best available evidence and according to the model proposed by the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system to elaborate clinical practice guidelines and to classify the quality of the evidence and the strength of the recommendations. These recommendations should be a reference to gynecologist and other health professionals involved in the treatment of postmenopausal women.

22 Guideline Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. 2013

Compston, J / Bowring, C / Cooper, A / Cooper, C / Davies, C / Francis, R / Kanis, J A / Marsh, D / McCloskey, E V / Reid, D M / Selby, P / Anonymous3800753. ·University of Cambridge School of Clinical Medicine, Cambridge, UK. jec1001@hermes.cam.ac.uk · ·Maturitas · Pubmed #23810490.

ABSTRACT: Since the launch in 2008 by the National Osteoporosis Guideline Group (NOGG), of guidance for the diagnosis and management of osteoporosis in postmenopausal women and older men in the UK there have been significant advances in risk assessment and treatment. These have been incorporated into an updated version of the guideline, with an additional focus on the management of glucocorticoid-induced osteoporosis, the role of calcium and vitamin D therapy and the benefits and risks of long-term bisphosphonate therapy. The updated guideline is summarised below. The recommendations in the guideline are intended to aid management decisions but do not replace the need for clinical judgement in the care of individuals in clinical practice.

23 Guideline [Normocalcemic primary hyperparathyroidism: recommendations for management and follow-up]. 2013

Martínez Díaz-Guerra, Guillermo / Jódar Gimeno, Esteban / Reyes García, Rebeca / Gómez Sáez, José Manuel / Muñoz-Torres, Manuel / Anonymous700761. ·Servicio de Endocrinología, Hospital Doce de Octubre, Madrid, España. · ·Endocrinol Nutr · Pubmed #23660008.

ABSTRACT: OBJECTIVE: To provide practical recommendations for evaluation and follow-up of patients with normocalcemic primary hyperparathyroidism. PARTICIPANTS: Members of the Bone Metabolism Working Group of the Spanish Society of Endocrinology. METHODS: A systematic search was made in MEDLINE (PubMed), using the terms normocalcemic primary hyperparathyroidism and primary hyperparathyroidism, for articles in English published before 22 November 2012. Literature was reviewed by 2 members of the Bone Metabolism Working Group of the Spanish Society of Endocrinology, and after development of recommendations, the manuscript was reviewed by all other members of the Group, and their suggestions were incorporated. CONCLUSIONS: The document provides practical recommendations for evaluation and follow-up of patients with normocalcemic primary hyperparathyroidism. There is however little evidence available about different aspects of this disease, mainly progression rate and clinical impact. More data are therefore needed before definite recommendations may be made.

24 Guideline [Guidelines for the diagnosis, prevention and treatment of osteoporosis. Italian Osteoporosis, Mineral Metabolism, and Skeletal Diseases Society]. 2013

Anonymous7150744. · ·Minerva Endocrinol · Pubmed #23539106.

ABSTRACT: -- No abstract --

25 Guideline The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. 2013

Anonymous5970744 / Ip, Ip / Cheung, Shing-Kee William / Cheung, Tak-Cheong / Choi, Tak-Cheong / Chow, Siu-Lun Eddie / Ho, Yiu-Yan Andrew / Kan, Sik-Yau Anita / Kung, Wai-Chee Annie / Lee, Ka-Kui / Leung, Ka-Li Frankie / Leung, Yin-Yan Jenny / Lo, Seen-Tsing Sue / Sy, Chung-Tai / Wong, Yat-Wa / Anonymous5980744. · ·Hong Kong Med J · Pubmed #23535738.

ABSTRACT: -- No abstract --

Next